Table 2 Selected variables to predict mortality risk based on the training set (N = 18,682) using Elastic-net logistic regression (“glmnet” R package), SCAD- support vector machine (“penalizedSVM” R package), and MCP- neural network algorithm with repeated tenfold cross-validation in the training set (“neuralnet” and “ncvreg” R packages).
Algorithm | Selected variables | Normalized importance value % | P-value |
---|---|---|---|
Elastic net-regularized logistic regression (Alpha hyperparameter:0.5, lambda tuning’s parameter:0.006196) | Age at dementia diagnosis | 100 | < 0.001 |
MMSE score | 85 | < 0.001 | |
BMI | 74 | < 0.001 | |
Basic dementia diagnostic work-up | 56 | < 0.001 | |
Diuretics | 45 | < 0.001 | |
Time from referral to initiation of work-up | 42 | 0.367 | |
Time from initiation of work-up to diagnosis | 37 | < 0.001 | |
Atorvastatin | 35 | < 0.001 | |
Statins | 35 | < 0.001 | |
Cholinesterase inhibitors | 32 | < 0.001 | |
Rosuvastatin | 32 | < 0.001 | |
Heart failure | 31 | 0.012 | |
Charlson comorbidity index | 27 | < 0.001 | |
Dementia medications | 25 | < 0.001 | |
Physiotherapist assessment | 22 | < 0.001 | |
Place of residency | 21 | 0.001 | |
Fluvastatin | 21 | 0.421 | |
Alcohol related diagnosis | 17 | < 0.001 | |
Renal disease | 15 | < 0.001 | |
Total number of medications at baseline | 14 | < 0.001 | |
Municipality | 13 | 0.626 | |
Sex | 12 | < 0.001 | |
Liver failure | 12 | 0.062 | |
Atrial fibrillation | 11 | < 0.001 | |
Anemia | 11 | < 0.001 | |
Ischemic heart failure | 10 | < 0.001 | |
Dementia type | 9 | < 0.001 | |
Diabetes mellitus | 8 | < 0.001 | |
Renin-angiotensin system inhibitors | 8 | 0.635 | |
Renin-angiotensin system inhibitors two or more years before dementia diagnosis | 8 | 0.449 | |
Losartan | 6 | 0.001 | |
Antidepressants | 3 | 0.135 | |
Irbesartan | 3 | 0.78 | |
Acute Kidney Injury | 2 | 0.003 | |
Cancer | 2 | 0.002 | |
Stroke | 2 | < 0.001 | |
Captopril | 2 | 0.038 | |
Calcium channel blockers | 2 | 0.367 | |
SCAD-regularized SVM (Kernel: sigmoid, Number of Support Vectors: 18,673, lambda tuning’s parameter:0.010) | Age at dementia diagnosis | 100 | < 0.001 |
MMSE score | 90 | < 0.001 | |
Basic dementia diagnostic work-up | 85 | < 0.001 | |
BMI | 83 | < 0.001 | |
Time from referral to diagnosis | 68 | < 0.001 | |
Time from referral to initiation of work-up | 67 | 0.367 | |
Time from initiation of work-up to diagnosis | 64 | < 0.001 | |
Physiotherapist assessment | 50 | < 0.001 | |
Charlson comorbidity index | 39 | < 0.001 | |
Diuretics | 35 | < 0.001 | |
Sex | 33 | < 0.001 | |
Dementia medications | 25 | < 0.001 | |
Atorvastatin | 25 | < 0.001 | |
Heart failure | 23 | 0.012 | |
Care unit (primary care vs specialist care) | 22 | < 0.001 | |
Rosuvastatin | 21 | < 0.001 | |
Statins | 18 | < 0.001 | |
Simvastatin | 17 | 0.722 | |
Total number of medications at baseline | 14 | < 0.001 | |
Diabetes mellitus | 7 | < 0.001 | |
Renin-angiotensin system inhibitors two or more years before dementia diagnosis | 7 | 0.449 | |
Hypertension | 5 | < 0.001 | |
Acute Kidney Injury | 3 | 0.003 | |
Cancer | 2 | 0.002 | |
Liver failure | 2 | 0.062 | |
MCP-regularized Backpropagation Neural Network (Softmax activation function, lambda tuning’s parameter:0.0020) | Age at dementia diagnosis | 100 | < 0.001 |
BMI | 89 | < 0.001 | |
MMSE score | 75 | < 0.001 | |
Diuretics | 51 | < 0.001 | |
Time from referral to initiation of work-up | 44 | 0.367 | |
Time from initiation of work-up to diagnosis | 42 | < 0.001 | |
Atorvastatin | 34 | < 0.001 | |
Basic dementia diagnostic work-up | 30 | < 0.001 | |
Sex | 25 | < 0.001 | |
Charlson comorbidity index | 21 | < 0.001 | |
Dementia medications | 20 | < 0.001 | |
Municipality | 18 | 0.626 | |
Total number of medications at baseline | 16 | < 0.001 | |
Heart failure | 16 | 0.012 | |
Physiotherapist assessment | 14 | < 0.001 | |
Care unit (primary care vs specialist care) | 14 | < 0.001 | |
Cholinesterase inhibitors | 13 | < 0.001 | |
Atrial fibrillation | 13 | < 0.001 | |
Rosuvastatin | 12 | < 0.001 | |
Place of residency | 11 | 0.001 | |
Alcohol related diagnosis | 10 | < 0.001 | |
Renin-angiotensin system inhibitors | 9 | 0.635 | |
Renin-angiotensin system inhibitors two or more years before dementia diagnosis | 9 | 0.449 | |
Dementia type | 8 | < 0.001 | |
Diabetes mellitus | 8 | < 0.001 | |
Blood tests | 7 | 0.902 | |
Losartan | 7 | 0.001 | |
Statins | 7 | < 0.001 | |
Antidepressants | 4 | 0.135 | |
Cardiovascular medication at diagnosis | 4 | < 0.001 | |
Renal disease | 4 | < 0.001 | |
Cancer | 3 | 0.002 | |
Irbesartan | 3 | 0.78 | |
Liver failure | 3 | 0.062 | |
Captopril | 2 | 0.038 | |
Valsartan | 2 | 0.096 | |
Calcium channel blockers | 2 | 0.367 | |
Heart failure | 2 | 0.359 | |
Fluvastatin | 1 | 0.421 | |
Anemia | 1 | < 0.001 |